KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2025)

Alnylam Pharmaceuticals' Raw Materials history spans 8 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 40.81% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $14.2 million, down 40.81%, while the annual FY2025 figure was $14.2 million, 40.81% down from the prior year.
  • Raw Materials reached $14.2 million in Q4 2025 per ALNY's latest filing, down from $22.3 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $65.2 million in Q3 2021 to a low of $14.2 million in Q4 2025.
  • Average Raw Materials over 5 years is $26.6 million, with a median of $22.6 million recorded in 2024.
  • Peak YoY movement for Raw Materials: tumbled 76.75% in 2021, then surged 51.25% in 2022.
  • A 5-year view of Raw Materials shows it stood at $14.8 million in 2021, then skyrocketed by 51.25% to $22.3 million in 2022, then increased by 4.62% to $23.3 million in 2023, then grew by 2.65% to $24.0 million in 2024, then crashed by 40.81% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Raw Materials are $14.2 million (Q4 2025), $22.3 million (Q3 2025), and $22.9 million (Q2 2025).